S100A8 and juvenile idiopathic arthritis: Various studies in RA and JIA have also reported MRP8/14 as a potential marker for predicting disease flare/relapse following treatment termination.40–42 For example, Gerss et al,43 identified MRP8/14 as a way of identifying patients with JIA, in clinical remission but not subclinical/immunological remission, who are at increased risk of disease flare within 6 months of stopping treatment.